Gesundheit Benjamin, Hochbaum Leah, Fetyukhina Alexandra, Vorobyev Vasily, Vorobyev Nikolay
Research and Development, Cell El Ltd., Jerusalem, ISR.
Intensive Care Unit, Special Hospital for Internal Medicine, Belgrade, SRB.
Cureus. 2025 May 4;17(5):e83440. doi: 10.7759/cureus.83440. eCollection 2025 May.
Autism spectrum disorder (ASD) is associated with significant lifelong challenges for severely affected children and their families. The condition remains poorly understood, and no reliable, effective treatments are available. Presented is a case of a boy with severe ASD, epilepsy, and a pathological electroencephalogram (EEG) who underwent five treatments between the ages of 5.75 years and nine years with mesenchymal stem cells from allogeneic placenta and umbilical cord tissue of unrelated donors. A significant clinical response was observed following each course, including the disappearance of seizures, normalization of the EEG after the first course, and continuously improved ASD symptoms, social skills, and emotional expression. Allogeneic mesenchymal stem cells might offer an attractive innovative modality for some children with ASD and may prove a promising therapy for children with seizure disorders. Clinical research directions are presented to develop these innovative treatments and design future research.
自闭症谱系障碍（ASD）给重度受影响的儿童及其家庭带来了重大的终身挑战。这种病症仍未得到充分了解，且尚无可靠、有效的治疗方法。本文介绍了一名患有重度ASD、癫痫和病理性脑电图（EEG）的男孩的病例，该男孩在5.75岁至9岁之间接受了5次来自无关供体的异体胎盘和脐带组织间充质干细胞治疗。每次治疗后均观察到显著的临床反应，包括癫痫发作消失、第一个疗程后脑电图恢复正常，以及ASD症状、社交技能和情感表达持续改善。异体间充质干细胞可能为一些患有ASD的儿童提供一种有吸引力的创新治疗方式，并且可能被证明是治疗癫痫症儿童的一种有前景的疗法。本文还提出了临床研究方向，以开发这些创新治疗方法并设计未来的研究。
